Adriamycin®
Doxorubicin is an anthracycline antibiotic widely used in the treatment of breast cancer, leukemias, lymphomas, and sarcomas. It intercalates into DNA and inhibits topoisomerase II.
| Dosage Form | IV Injectable (Solution) |
| Strength | 2 mg/mL; 10 mg, 20 mg, 50 mg vials |
| Storage | Store at 2–8°C. Protect from light. |
| Category | Oncology |
| Availability | Available for Transfer |
Acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, breast cancer, ovarian cancer, soft tissue sarcoma, Wilms tumor, neuroblastoma.
Intercalates between DNA base pairs and inhibits topoisomerase II, preventing DNA religation. Also generates free radicals that cause DNA and cell membrane damage.
Each Burrard Pharmaceuticals technology transfer package for Doxorubicin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.